

PATIENCE: A study to evaluate a standardized approach to treatment of NTM disease (NTM-OB-17 (PATIENCE))

Summary

This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of treatment of nontuberculous mycobacteria (NTM) in people with CF.

This study is for people with cystic fibrosis who were followed in the PREDICT study until they developed NTM disease. Researchers will evaluate how people respond to an NTM treatment algorithm that follows current standard guidelines.

Specimen Information

Status: Specimens are Not yet available, anticipated November, 2024

Blood and urine are collected at the start of treatment for NTM disease, at the end of treatment and at the last follow up (which occurs approximately 1 year after the end of treatment).

Visit #	Time From Baseline	Specimens Collected
1	+0 Days	EDTA plasma, Serum, Urine
2	+12 Months	EDTA plasma, Serum, Urine
3	+24 Months	EDTA plasma, Serum, Urine

Study Design

Study Type? Observational

Randomized Study? No

Placebo Controlled? No

Length of Participation 5 Years

Number of Study Visits? 20

Additional Information

Phase? Not Applicable

Study Sponsor? Nick, Jerry

Study Drugs? N/A

 Eligibility

Age	6 Years and Older
Mutation(s)	No Mutation Requirement
FEV1% Predicated	No FEV1 Limit
PA Status	N/A
Other	Participants have to have been enrolled in the PREDICT study and have been diagnosed with NTM disease.

Study Results

STUDY RESULTS NOT YET AVAILABLE

For more information about the results of this study and where it was conducted, visit [ClinicalTrials.gov](https://clinicaltrials.gov).